-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 3, 2021, Antios Therapeutics announced the completion of a US$75 million B-1 round of financing to develop innovative therapies for functional cures of chronic hepatitis B virus (HBV) infection
ATI-2173 is a new type of oral ASPIN molecule designed to deliver the 5'-monophosphate of clevudine to the liver
So far, preclinical data of ATI-2173 as a single agent or in combination with tenofovir disoproxil fumarate (TDF) show that it has the ability to continuously inhibit HBV DNA levels
Reference materials:
[1] Antios Therapeutics Raises $75 Million in a Series B-1 Funding to Advance Clinical Programs for HBV.
(The original text has been deleted)